#1 Clinical Trials Search in Europe

Dexamethasone Sodium Phosphate Ph. Eur.

This article discusses several clinical trials investigating the use of Dexamethasone Sodium Phosphate in combination with other drugs for the treatment of multiple myeloma. These studies aim to evaluate the safety and efficacy of various drug combinations in patients with newly diagnosed or relapsed/refractory multiple myeloma. The trials explore different administration methods and dosing regimens to optimize treatment outcomes and patient experience.

Table of Contents

What is Dexamethasone Sodium Phosphate?

Dexamethasone Sodium Phosphate (also known as DexaGalen® 8 mg injekt) is a powerful synthetic corticosteroid medication used to treat various medical conditions[1]. It belongs to a class of drugs called glucocorticoids, which are similar to natural hormones produced by the adrenal glands. Dexamethasone is known for its potent anti-inflammatory and immunosuppressive properties, making it useful in treating a wide range of diseases and conditions.

Medical Uses

Dexamethasone Sodium Phosphate is primarily used in the treatment of:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells. Dexamethasone is often used in combination with other drugs to treat this condition[2].
  • Inflammatory Conditions: Such as severe allergies, arthritis, and certain skin conditions.
  • Autoimmune Disorders: Where the immune system attacks the body’s own tissues.
  • Brain Swelling: To reduce inflammation in the brain caused by various conditions.
  • Nausea and Vomiting: Particularly in cancer patients undergoing chemotherapy.

Administration

Dexamethasone Sodium Phosphate is typically administered as an intravenous (IV) injection or infusion[3]. This means it is given directly into a vein, usually by a healthcare professional. The method of administration allows for quick action and precise dosing, which is particularly important in acute situations or when treating severe conditions.

Dosage

The dosage of Dexamethasone Sodium Phosphate can vary widely depending on the condition being treated, the patient’s age, weight, and overall health status. In clinical trials for multiple myeloma, dosages have ranged from 20 mg to 40 mg per day[1][2]. However, it’s crucial to understand that dosage is always determined by a healthcare provider and should never be adjusted without medical supervision.

Potential Side Effects

Like all medications, Dexamethasone Sodium Phosphate can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Changes in mood or behavior
  • Elevated blood sugar levels
  • Fluid retention
  • Insomnia
  • Osteoporosis (with long-term use)
  • Gastrointestinal issues

It’s important to discuss any side effects with your healthcare provider, as they can often be managed or mitigated[4].

Precautions and Considerations

When taking Dexamethasone Sodium Phosphate, there are several important precautions to keep in mind:

  • Pregnancy and Breastfeeding: The medication may not be suitable for pregnant or breastfeeding women. Discuss with your doctor if you are pregnant, planning to become pregnant, or breastfeeding[2].
  • Contraception: Both male and female patients may need to use effective contraception methods during treatment and for some time after[2].
  • Infections: Dexamethasone can suppress the immune system, increasing the risk of infections. Inform your doctor of any signs of infection[4].
  • Other Medical Conditions: Inform your doctor about any other medical conditions you have, especially liver, kidney, or heart problems, diabetes, or a history of mental health issues[4].

Ongoing Research

Dexamethasone Sodium Phosphate continues to be the subject of ongoing clinical research, particularly in the treatment of multiple myeloma. Current studies are exploring its use in combination with other drugs like isatuximab, lenalidomide, bortezomib, and carfilzomib[1][2][3][4]. These trials aim to improve treatment outcomes for patients with various stages of multiple myeloma, including newly diagnosed cases and those with relapsed or refractory disease.

As research progresses, we may gain new insights into the optimal use of Dexamethasone Sodium Phosphate, potentially leading to more effective treatment strategies for multiple myeloma and other conditions.

Trial Aspect Details
Drug Combinations Dexamethasone Sodium Phosphate is used in combination with various drugs including isatuximab, carfilzomib, lenalidomide, and bortezomib
Patient Populations Newly diagnosed multiple myeloma patients not eligible for transplant, and patients with relapsed/refractory multiple myeloma
Administration Methods Intravenous infusion, with some trials exploring subcutaneous administration
Primary Endpoints Progression-free survival (PFS), overall response rate (ORR), safety and tolerability
Secondary Endpoints Overall survival, minimal residual disease negativity, quality of life measures, pharmacokinetics
Dosage Varies by trial, with maximum daily doses ranging from 20mg to 40mg
Trial Durations Range from several months to over 2 years, depending on the specific trial design

FAQ

  • What is Dexamethasone Sodium Phosphate? Dexamethasone Sodium Phosphate is a corticosteroid medication used in the treatment of multiple myeloma. It is often combined with other drugs to enhance their effectiveness in fighting cancer cells.
  • How is Dexamethasone Sodium Phosphate administered in these trials? In the trials discussed, Dexamethasone Sodium Phosphate is typically administered intravenously (through a vein) in combination with other medications. The dosage and frequency may vary depending on the specific trial protocol.
  • What types of multiple myeloma patients are included in these trials? The trials include patients with various stages of multiple myeloma, including newly diagnosed patients not eligible for transplant, as well as those with relapsed or refractory disease who have received prior treatments.
  • What are some common side effects of Dexamethasone Sodium Phosphate? While specific side effects are not detailed in the trial information provided, common side effects of Dexamethasone can include increased appetite, weight gain, mood changes, and increased blood sugar levels. The trials monitor patients for adverse events and safety concerns.
  • How long do these clinical trials typically last? The duration of these trials varies, but they can last for several months to years. Some trials mention treatment periods of up to 115 weeks (about 2.2 years), while others may continue as long as the patient is benefiting from the treatment.

Ongoing Clinical Trials on Dexamethasone Sodium Phosphate Ph. Eur.

  • Testing Aganirsen Eye Drops in Patients with Corneal Blood Vessel Growth from Herpes Eye Disease Before Corneal Transplant Surgery

    Recruiting

    2 1 1
    Investigated drugs:
    Germany

  • Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Finland France Greece Italy Spain +1

  • Study on the Effects of Isatuximab with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Greece Italy +5

  • Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Greece Hungary +5

  • Study on Isatuximab, Carfilzomib, and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Greece Portugal

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell found in bone marrow. It can cause bone pain, kidney problems, and weakened immune system.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse. This is an important measure of how well a cancer treatment works.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment. It includes patients with partial and complete responses to treatment.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment. Being MRD negative means that no cancer cells are detected using very sensitive tests.
  • Relapsed/Refractory Multiple Myeloma: Multiple myeloma that has returned after a period of remission or has not responded to previous treatments.
  • Intravenous (IV) Infusion: A method of delivering medications directly into a vein using a needle or catheter.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This helps determine the best dosing and administration methods.
  • Health-Related Quality of Life (HRQL): A patient's perceived physical and mental health over time. It is an important measure in cancer treatment to ensure that therapies improve not just survival but also well-being.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment. This does not always mean the cancer has been cured.

References

  1. http://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-isatuximab-for-adults-with-multiple-myeloma-benefiting-from-isatuximab-therapy/
  2. http://clinicaltrials.eu/trial/study-of-isatuximab-lenalidomide-and-dexamethasone-for-patients-with-high-risk-smoldering-multiple-myeloma/
  3. http://clinicaltrials.eu/trial/study-on-isatuximab-carfilzomib-and-dexamethasone-for-adults-with-relapsed-or-refractory-multiple-myeloma/
  4. http://clinicaltrials.eu/trial/study-on-the-effects-of-isatuximab-with-bortezomib-lenalidomide-and-dexamethasone-for-patients-with-newly-diagnosed-multiple-myeloma-not-eligible-for-transplant/